Patents by Inventor Kenichiro Shimokawa
Kenichiro Shimokawa has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11236099Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.Type: GrantFiled: June 19, 2018Date of Patent: February 1, 2022Assignee: Takeda Pharmaceutical Company LimitedInventors: Kazuaki Takami, Masaki Seto, Shinobu Sasaki, Haruhi Ando, Masaki Ogino, Tomoko Ohashi, Toshihiro Imaeda, Ikuo Fujimori, Yasuhiro Tsukimi, Masami Yamada, Kenichiro Shimokawa, Takeshi Wakabayashi, Masataka Murakami, Makoto Fushimi, Tomohiro Okawa, Jinichi Yonemori, Tomohiro Ohashi, Hideo Suzuki, Hironobu Maezaki, Ayumu Sato, Yasutomi Asano, Steve Swann
-
Publication number: 20220017530Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.Type: ApplicationFiled: September 15, 2021Publication date: January 20, 2022Applicant: Takeda Pharmaceutical Company LimitedInventors: Kazuaki Takami, Masaki Seto, Shinobu Sasaki, Haruhi Ando, Masaki Ogino, Tomoko Ohashi, Toshihiro Imaeda, Ikuo Fujimori, Yasuhiro Tsukimi, Masami Yamada, Kenichiro Shimokawa, Takeshi Wakabayashi, Masataka Murakami, Makoto Fushimi, Tomohiro Okawa, Jinichi Yonemori, Tomohiro Ohashi, Hideo Suzuki, Hironobu Maezaki, Ayumu Sato, Yasutomi Asano, Steve Swann
-
Patent number: 11034700Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: GrantFiled: March 7, 2018Date of Patent: June 15, 2021Assignee: Takeda Pharmaceutical Company LimitedInventors: Satoshi Mikami, Masaki Daini, Yuhei Miyanohana, Hideo Suzuki, Kenichiro Shimokawa, Yuichi Kajita, Masaki Ogino, Tatsuki Koike, Kohei Takeuchi
-
Publication number: 20210139491Abstract: The present invention aims to provide a compound that may be useful for the prophylaxis or treatment of constipation and the like. The present invention provides a compound represented by the following formula (I): wherein each symbol is as described in the specification, or a salt thereof.Type: ApplicationFiled: June 19, 2018Publication date: May 13, 2021Inventors: Kazuaki TAKAMI, Masaki SETO, Shinobu SASAKI, Haruhi ANDO, Masaki OGINO, Tomoko OHASHI, Toshihiro IMAEDA, Ikuo FUJIMORI, Yasuhiro TSUKIMI, Masami YAMADA, Kenichiro SHIMOKAWA, Takeshi WAKABAYASHI, Masataka MURAKAMI, Makoto FUSHIMI, Tomohiro OKAWA, Jinichi YONEMORI, Tomohiro OHASHI, Hideo SUZUKI, Hironobu MAEZAKI, Ayumu SATO, Yasutomi ASANO, Steve SWANN
-
Patent number: 10899752Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.Type: GrantFiled: April 25, 2019Date of Patent: January 26, 2021Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masataka Murakami, Jinichi Yonemori, Takuto Kojima
-
Publication number: 20200392149Abstract: The present invention provides a substituted pyrrolidine compound having an orexin type 2 receptor agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the specification, or a salt thereof, has an orexin type 2 receptor agonist activity, and is useful as an agent for the prophylaxis or treatment of narcolepsy.Type: ApplicationFiled: March 7, 2018Publication date: December 17, 2020Applicant: Takeda Pharmaceutical Company LimitedInventors: Satoshi MIKAMI, Masaki DAINI, Yuhei MIYANOHANA, Hideo SUZUKI, Kenichiro SHIMOKAWA, Yuichi KAJITA, Masaki OGINO, Tatsuki KOIKE, Kohei TAKEUCHI
-
Publication number: 20200163970Abstract: Provided is a novel compound or salt thereof that induces degradation by autophagy of an intracellular molecule. In this compound, a ligand having activity to bind to an intracellular molecule and a structure having activity to induce autophagy of an intracellular molecule are linked via a linker without loss of the activity of the ligand and the structure.Type: ApplicationFiled: February 2, 2018Publication date: May 28, 2020Inventors: Hirokazu ARIMOTO, Kaori ITTO, Daiki TAKAHASHI, Nobuo CHO, Hiroshi NARA, Kenichiro SHIMOKAWA, Taiichi OHRA, Shigekazu SASAKI, Naoki ISHII
-
Patent number: 10548899Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.Type: GrantFiled: October 19, 2016Date of Patent: February 4, 2020Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masaki Ogino, Eiji Kimura, Masataka Murakami, Takuto Kojima, Jinichi Yonemori
-
Patent number: 10428056Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.Type: GrantFiled: August 27, 2018Date of Patent: October 1, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masataka Murakami, Jinichi Yonemori, Takuto Kojima
-
Publication number: 20190248776Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.Type: ApplicationFiled: April 25, 2019Publication date: August 15, 2019Inventors: Takahiro SUGIMOTO, Shinkichi SUZUKI, Hiroki SAKAMOTO, Masami YAMADA, Minoru NAKAMURA, Makoto KAMATA, Kenichiro SHIMOKAWA, Masaki OGINO, Eiji KIMURA, Masataka MURAKAMI, Jinichi YONEMORI, Takuto KOJIMA
-
Patent number: 10323027Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.Type: GrantFiled: June 23, 2016Date of Patent: June 18, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masataka Murakami, Jinichi Yonemori, Takuto Kojima
-
Patent number: 10208046Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as medicaments such as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like, and the like. The present invention relates to a compound represented by the formula (I) wherein ring A is an optionally substituted 5- or 6-membered ring; R is a C1-6 alkyl group substituted by 1 to 5 halogen atoms; and X is —CH? or —N?, or a salt thereof.Type: GrantFiled: May 15, 2015Date of Patent: February 19, 2019Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahiro Sugimoto, Kenichiro Shimokawa, Takuto Kojima, Hiroki Sakamoto, Ikuo Fujimori, Minoru Nakamura, Masami Yamada, Masataka Murakami, Makoto Kamata, Shinkichi Suzuki
-
Publication number: 20180362516Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.Type: ApplicationFiled: August 27, 2018Publication date: December 20, 2018Inventors: Takahiro SUGIMOTO, Shinkichi SUZUKI, Hiroki SAKAMOTO, Masami YAMADA, Minoru NAKAMURA, Makoto KAMATA, Kenichiro SHIMOKAWA, Takuto KOJIMA
-
Publication number: 20180303841Abstract: The present invention provides a compound which has a cholinergic muscarinic M1 receptor positive allosteric modulator activity and may be useful as a medicament such as an agent for the prophylaxis or treatment of Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, Lewy body dementia and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof. In the formula (I), each symbol is as described in the attached specification.Type: ApplicationFiled: October 19, 2016Publication date: October 25, 2018Inventors: Takahiro SUGIMOTO, Shinkichi SUZUKI, Hiroki SAKAMOTO, Masami YAMADA, Minoru NAKAMURA, Makoto KAMATA, Kenichiro SHIMOKAWA, Masaki OGINO, Eiji KIMURA, Masataka MURAKAMI, Takuto KOJIMA, Jinichi YONEMORI
-
Patent number: 10087150Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.Type: GrantFiled: October 31, 2017Date of Patent: October 2, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Takuto Kojima
-
Publication number: 20180162850Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.Type: ApplicationFiled: June 23, 2016Publication date: June 14, 2018Inventors: Takahiro SUGIMOTO, Shinkichi SUZUKI, Hiroki SAKAMOTO, Masami YAMADA, Minoru NAKAMURA, Makoto KAMATA, Kenichiro SHIMOKAWA, Masaki OGINO, Eiji KIMURA, Masataka MURAKAMI, Jinichi YONEMORI, Takuto KOJIMA
-
Publication number: 20180050996Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.Type: ApplicationFiled: October 31, 2017Publication date: February 22, 2018Inventors: Takahiro SUGIMOTO, Shinkichi SUZUKI, Hiroki SAKAMOTO, Masami YAMADA, Minoru NAKAMURA, Makoto KAMATA, Kenichiro SHIMOKAWA, Takuto KOJIMA
-
Patent number: 9878989Abstract: The present invention provides a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, which may be useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder, Parkinson's disease dementia, dementia with Lewy bodies and the like. The present invention relates to a compound represented by the formula (I) or a salt thereof: wherein each symbol is as defined in the attached DESCRIPTION.Type: GrantFiled: June 23, 2016Date of Patent: January 30, 2018Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahiro Sugimoto, Shinkichi Suzuki, Hiroki Sakamoto, Masami Yamada, Minoru Nakamura, Makoto Kamata, Kenichiro Shimokawa, Masataka Murakami, Jinichi Yonemori, Takuto Kojima
-
Patent number: 9777005Abstract: Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, and useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder and the like. The present invention relates to a compound represented by the formula wherein ring A is a 4- to 7-membered ring optionally having substituent(s); L is —O—, —S—, —SO— or —SO2—; R1 is a C1-6 alkyl group optionally having substituent(s) (provided that when L is —O—, R1 is not a C1-6 alkyl group optionally substituted by halogen atom(s)), or a cyclic group optionally having substituent(s); X1 is —CRa? or —N?; X2 is —CRb? or —N?; X3 is —CRc= or —N?; Ra, Rb and Rc are each a C1-6 alkyl group, C2-6 alkenyl group, C1-6 alkoxy group, C3-6 cycloalkyl group, C3-6 cycloalkoxy group or C6-14 aryl group, each of which optionally having substituent(s), H or halogen, or a salt thereof.Type: GrantFiled: November 18, 2013Date of Patent: October 3, 2017Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Shinkichi Suzuki, Masami Yamada, Makoto Kamata, Takuto Kojima, Ikuo Fujimori, Kenichiro Shimokawa
-
Patent number: 9732086Abstract: Provided is a compound having a cholinergic muscarinic M1 receptor positive allosteric modulator activity, and useful as a prophylactic or therapeutic drug for Alzheimer's disease, schizophrenia, pain, sleep disorder and the like. The present invention relates to a compound represented by the formula wherein ring A is a 4- to 7-membered ring optionally having substituent(s); L is —O—, —S—, —SO— or —SO2—; R1 is a C1-6 alkyl group optionally having substituent(s) (provided that when L is —O—, R1 is not a C1-6 alkyl group optionally substituted by halogen atom(s)), or a cyclic group optionally having substituent(s); X1 is —CRa? or —N?; X2 is —CRb? or —N?; X3 is —CRc= or —N?; Ra, Rb and Rc are each a C1-6 alkyl group, C2-6 alkenyl group, C1-6 alkoxy group, C3-6 cycloalkyl group, C3-6 cycloalkoxy group or C6-14 aryl group, each of which optionally having substituent(s), H or halogen, or a salt thereof.Type: GrantFiled: November 18, 2013Date of Patent: August 15, 2017Assignee: Takeda Pharmaceutical Company LimitedInventors: Takahiro Sugimoto, Minoru Nakamura, Hiroki Sakamoto, Shinkichi Suzuki, Masami Yamada, Makoto Kamata, Takuto Kojima, Ikuo Fujimori, Kenichiro Shimokawa